Stock OCUP OCUPHIRE PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/06/2024 BST 		5-day change 1st Jan Change
1.535 USD +0.33% Intraday chart for Ocuphire Pharma, Inc. +0.33% -49.00%
06-06 Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June CI
05-10 Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June
AQ
Diabetic Retinopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
AQ
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
AQ
Ocuphire Pharma to Present at the Aegis Virtual Conference
AQ
Ocuphire Pharma Announces Presentation on APX3330 at the ARVO 2024 Annual Meeting
AQ
Ocuphire Pharma to Present at the Aegis Virtual Conference
AQ
Ocuphire Pharma Announces APX3330 Presentation at ARVO 2024 Annual Meeting
AQ
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
AQ
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
AQ
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
AQ
Ocuphire Pharma to Present in the BIO CEO and Investor Conference
AQ
Ocuphire Pharma to Present in the BIO CEO & Investor Conference
AQ
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
AQ
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
AQ
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
AQ
Ocuphire Pharma : Management Change/Compensation - Form 8-K
PU
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCUP Stock
  4. News Ocuphire Pharma, Inc.
  5. Press Releases